SER-109 Results in Increase in Microbe-Producing Metabolites
The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.
Taha Qazi, MD: Male Sexual Dysfunction Following Ulcerative Colitis Surgery
Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.
TNF-Antagonist Therapy Linked to Better Outcomes for Post-Operative Crohn’s Disease
Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.
DDW Research Shows No Efficacy for Vedolizumab in Treating NAFLD
Patients with IBD are often at an increased risk of developing NAFLD.
Bariatric Surgery Linked to Improved Outcomes After Myocardial Infarction
New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.
Ken Blount, PhD: Effect of RBX2660 on Microbiome and Bile Acid Composition
Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.
Long-Term Assessments Needed to Evaluate Impact of Accelerated Aging on EoE Progression
Post-treatment, data show molecular age remained significantly greater than chronological age at a median difference of 18.6 years.
Ustekinumab, Ozanimod Have Comparable Profiles for Ulcerative Colitis
The data presented at DDW show similar safety and efficacy for the 2 treatments.
RBX2660 Reduces Risk of CDI Recurrence at Week 8
Recurrence commonly occurred during the first 2 weeks regardless of treatment.
Acid Suppression Results in a Decrease in Mortality for GERD Patients Following Lung Transplantation
Both post-transplant PPI and histamine-2 receptor antagonist use were independently associated with reduced risk of 1-year mortality.
Higher Adherence to DASH Diet Linked to Stronger Protection Against NAFLD Risk
DASH diet was inversely associated with NAFLD risk, independent of BMI changes.
Ribavirin Not Effective, Safe for Genotype 3 HCV
The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.
Anti-TNF, Ustekinumab Have Similar Efficacies Against Crohn’s Disease
There remains a need for longer-term observational studies comparing the 2 treatments.
COVID-19 Pandemic Response the Blueprint for Reducing C Difficile Impact
Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.
David M. Poppers, MD: Early Detection for Esophageal Cancer
Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.
Ustekinumab Effective Treating Extra-Intestinal Manifestations of Crohn's Disease
Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.
Brian E. Lacy, MD, PhD: IBS-C Symptoms During COVID-19
A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.
Sheldon Sloan, MD: The Promise of Etrasimod at DDW
Arena Pharmaceuticals expects to move forward with later phase clinical trials testing etrasimod.
Christopher V. Almario, MD: Treatment and Prevalence of Opioid-Induced Constipation
Patients with opioid-induced constipation had more frequent, painful constipation symptoms, compared to those with chronic idiopathic constipation.
David M. Poppers, MD, PhD: A Promising New Esophageal Adenocarcinoma Tool
Direct optical endoscopy are often underutilized in screenings for EAC.
Jordan Axelrad, MD: Role of Infections in Gut Microbiome Signature
Data show patients with IBD and pathogen produced a unique pathogen-specific microbiome.
Evan Dellon, MD: Increasing Biopsies for Esophagitis Diagnosis
Dr. Evan Dellon said up to 8 biopsies for high risk patients could be beneficial in diagnosing different diseases impacting the esophagus.
Joshua Bender: The Impact of COVID-19 on Liver Injuries
COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.
Sucrase Isomaltese Deficiency Prevalent in Patients with IBS-D
Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.
Higher Adalimumab Trough Level Not Linked to Increased Adverse Events in IBD Treatment
Data show adverse events occurred in 6.67% in the cohort of patients with IBD.
Vedolizumab Safe and Effective Treating Inflammatory Bowel Disease
Most of the data on vedolizumab has been limited by small sample sizes and short follow-up.
Charles Owen, MD: An Overview on Cologuard at DDW
About a quarter of Cologuard's ordered by patients are deemed to be inappropriate.
Florian Rieder, MD: Ozanimod as a Treatment for Ulcerative Colitis
Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.
RBX2660 Shows Promise as a C Difficile Treatment
The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.
Acute Pancreatitis Linked to Adverse Outcomes in Patients with Bone Marrow Transplantation
Data show adverse outcomes include increased mortality rates, prolonged hospital stay, and higher hospitalization chargers.